For research use only
| Cat No. | ABC-RC010Y |
| Product Type | Reporter Stable Cell Lines |
| Cell Type | Epithelial |
| Species | Mouse |
| Host Cell | KLN205 |
| Source Organ | Lung |
| Disease | Squamous Cell Carcinoma |
| Storage | Liquid Nitrogen |
KLN205/NFκB Reporter (Luc) Stable Cell Line enables high-sensitivity bioluminescent monitoring of NFκB signaling in cancer inflammation research.
KLN205/NFκB Reporter (Luc) Stable Cell Line is a bioluminescent reporter model engineered from murine lung squamous carcinoma KLN205 cells, featuring stable integration of a luciferase gene under NFκB-responsive promoter elements. This engineered cell line maintains the epithelial morphology and tumorigenic features of parental KLN205 cells while enabling quantitative, real-time monitoring of NFκB signaling activity. The reporter responds sensitively to pro-inflammatory cytokines such as TNF-α and IL-1β, pathogen-associated molecular patterns, and pharmacological modulators. Applications include inflammation–cancer crosstalk studies, tumor microenvironment research, high-throughput screening of NFκB modulators, and evaluation of drug resistance mechanisms. All cells are rigorously tested and confirmed negative for mycoplasma, fungi, yeast, and bacteria.
| Species | Mouse |
| Cat.No | ABC-RC010Y |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Disease | Squamous Cell Carcinoma |
| Biosafety Level | 2 |
| Storage | Liquid Nitrogen |
| Product Type | Reporter Stable Cell Lines |
| Host Cell | KLN205 |
| Gene Info | Luciferase (NFκB-responsive reporter) |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
The KLN205/NFκB Reporter (Luc) Stable Cell Line provides a highly sensitive luciferase-based system for monitoring NFκB signaling in real time. It enables quantitative assessment of inflammatory responses, innate immune signaling, and drug-induced NFκB activation, making it an excellent platform for high-throughput inhibitor screening and mechanistic studies in lung squamous carcinoma research.